10.24
-0.345(-3.26%)
Currency In USD
| Previous Close | 10.58 |
| Open | 10.57 |
| Day High | 10.68 |
| Day Low | 10 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 1.26M |
| Average Volume | 849,801 |
| Market Cap | 782.46M |
| PE | -3.94 |
| EPS | -2.6 |
| Moving Average 50 Days | 11.68 |
| Moving Average 200 Days | 15.34 |
| Change | -0.35 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $538.4 as of August 18, 2025 at a share price of $10.235. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $648.2 as of August 18, 2025 at a share price of $10.235.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
GlobeNewswire Inc.
Jul 07, 2025 11:00 AM GMT
Regulatory momentum builds for bexobrutideg with multiple designations across the United States and EU, Including EMA PRIME and FDA Fast Track for CLL/SLLSAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a cl
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
GlobeNewswire Inc.
Jun 12, 2025 11:00 AM GMT
Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in patients with WM Bexobrutideg was well tolerated with no new safety signals observed with longer duration on study or higher doses Data reinforce
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
GlobeNewswire Inc.
Jun 06, 2025 11:00 AM GMT
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announ